Literature DB >> 15824067

Optimizing the exogenous antigen loading of monocyte-derived dendritic cells.

Detlef Dieckmann1, Erwin S Schultz, Bernhard Ring, Patrick Chames, Gerhard Held, Hennie R Hoogenboom, Gerold Schuler.   

Abstract

Dendritic cell (DC) vaccination, i.e. the adoptive transfer of antigen-loaded DC, is still at an early stage and requires standardization. In this study, we investigated the exogenous loading of monocyte-derived DCs with HLA class I- and II-restricted peptides, as despite widespread use, little effort has been put into its pre-clinical validation. We found that only mature DCs (m-DC) but not immature DCs (im-DC) could be sufficiently loaded with exogenous class I-restricted peptides and were by far superior in expanding CD8(+) primary (Melan-A.A2 peptide-specific) and recall [Influenza matrix peptide (IMP) A2-specific] T cell responses. Primary stimulation with peptide-loaded im-DCs even down-regulated antigen-specific T cell responses. Our results indicate that stimulation with m-DCs is superior in terms of quantity and quality compared with im-DCs, supporting their preferred use in clinical DC trials. Loading of m-DCs with high (10 microM) concentrations generated clearly more Melan-A effectors than loading with 1 or 0.1 microM without any negative effect on the quality (affinity) of the resulting T cells. In contrast to the findings with the Melan-A peptide loading with 10 microM IMP was counter-productive, induced apoptosis and yielded fewer specific T cells of inferior affinity as compared with loading with 1 or 0.1 microM. In sharp contrast to the situation for HLA class I, much higher levels and longer half-lives of peptide-HLA class II complexes were obtainable upon loading of im-DCs with exogenous peptide, but m-DCs were functionally preferable to induce T(h)1 responses in vitro. Another surprising finding was that, while presentation to T cells upon simultaneous loading of several peptides with highly varying affinities and competing for the same class I or II molecule was possible, in priming experiments peptide competition clearly inhibited T cell induction. Although peptides will obviously vary in their individual properties, our study clearly points to some important principles that should be taken into account.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824067     DOI: 10.1093/intimm/dxh243

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells.

Authors:  Xiao-Li Huang; Zheng Fan; Luann Borowski; Charles R Rinaldo
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

2.  A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Authors:  Michael A Eller; Bonnie M Slike; Josephine H Cox; Emil Lesho; Zhining Wang; Jeffrey R Currier; Janice M Darden; Victoria R Polonis; Maryanne T Vahey; Sheila Peel; Merlin L Robb; Nelson L Michael; Mary A Marovich
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

3.  Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine.

Authors:  Christian Adam; Josef Mysliwietz; Ralph Mocikat
Journal:  J Transl Med       Date:  2007-03-14       Impact factor: 5.531

4.  Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation.

Authors:  Otto Luiz Dutra Cerqueira; Maria Alejandra Clavijo-Salomon; Elaine Cristina Cardoso; Tharcisio Citrangulo Tortelli Junior; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.